Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2016

7 - 11 Oct 2016

Bella Center, Copenhagen, Denmark

ESMO 2016: Financial difficulties linked to worse outcomes from cancer treatment

ESMO 2016: Financial difficulties linked to worse outcomes from cancer treatment

ESMO 2016: Single-arm trials for early access to cancer drugs

ESMO 2016: Single-arm trials for early access to cancer drugs

ESMO 2016: First feasibility study of the ESMO-MCBS scale in rare tumour entities

ESMO 2016: First feasibility study of the ESMO-MCBS scale in rare tumour entities

ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

ESMO 2016: MEK inhibition in KRAS-mutant NSCLC did not improve survival

ESMO 2016: MEK inhibition in KRAS-mutant NSCLC did not improve survival

ESMO 2016: Significant survival gains from neoadjuvant chemo for high-risk soft tissue sarcoma

ESMO 2016: Significant survival gains from neoadjuvant chemo for high-risk soft tissue sarcoma

ESMO 2016: Custirsen shows no survival benefits in metastatic prostate cancer

ESMO 2016: Custirsen shows no survival benefits in metastatic prostate cancer

ESMO 2016: Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

ESMO 2016: Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

ESMO 2016: Nintedanib improves PFS but not OS in phase III trial of metastatic colorectal cancer

ESMO 2016: Nintedanib improves PFS but not OS in phase III trial of metastatic colorectal cancer

ESMO 2016: Greater patient selection may be needed for first line nivolumab to improve PFS in advanced lung cancer

ESMO 2016: Greater patient selection may be needed for first line nivolumab to improve PFS in advanced lung cancer

ESMO 2016: Ceritinib provides longer PFS than chemo in trial of ALK rearranged lung cancer treatment

ESMO 2016: Ceritinib provides longer PFS than chemo in trial of ALK rearranged lung cancer treatment

ESMO 2016: Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

ESMO 2016: Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1...

ESMO 2016: Nivolumab maintains function and reduces symptoms in relapsed metastatic head and neck cancer

ESMO 2016: Nivolumab maintains function and reduces symptoms in relapsed metastatic head and neck cancer

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

ESMO 2016: True burden of head and neck cancer in France underestimated by more than one-third

ESMO 2016: True burden of head and neck cancer in France underestimated by more than one-third

ESMO 2016: Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify responders

ESMO 2016: Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify responders

ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

ESMO 2016: Targeting oestrogen receptor improves progression-free survival in advanced breast cancer

ESMO 2016: Targeting oestrogen receptor improves progression-free survival in advanced breast cancer

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

ESMO 2016: Ribociclib improves progression-free survival in advanced breast cancer

ESMO 2016: Ribociclib improves progression-free survival in advanced breast cancer

ESMO 2016: Biomarker Ki67 may help avoid biopsy in older breast cancer patients

ESMO 2016: Biomarker Ki67 may help avoid biopsy in older breast cancer patients

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

ESMO 2016: Improving cancer screening participation should be a priority

ESMO 2016: Improving cancer screening participation should be a priority

ESMO 2016: Thousands of melanoma patients in Europe have no access to new drugs

ESMO 2016: Thousands of melanoma patients in Europe have no access to new drugs

ESMO 2016: Combination therapy shows higher response and lower toxicity in paediatric brain cancer trial

ESMO 2016: Combination therapy shows higher response and lower toxicity in paediatric brain cancer trial

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

ESMO 2016: Frontline PARP inhibitor shrinks tumours in BRCA-positive breast patients

ESMO 2016: Frontline PARP inhibitor shrinks tumours in BRCA-positive breast patients

ESMO 2016: Reporting of adverse events in targeted therapy and immunotherapy trials is “suboptimal”

ESMO 2016: Reporting of adverse events in targeted therapy and immunotherapy trials is “suboptimal”

ESMO 2016: Impact of cognitive functions on oral cancer therapies

ESMO 2016: Impact of cognitive functions on oral cancer therapies

More from ecancer